Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | C1S | P09871 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46640 | 0.83 | CA2 (0.56) | MEN1KMT2AKDM4ESMN1; SMN2ATM | |
| SCHEMBL8636389 | 0.81 | MEN1 (0.46) | HAO1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL20863116 | 0.80 | F2 (0.52) | HAO1F2PLGPRSS1PRSS2 | |
| SCHEMBL4869439 | 0.79 | ALDH1A1 (0.47) | HAO1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2398565 | 0.79 | POLB (0.48) | MEN1KMT2AKDM4ESMN1; SMN2ATM | |
| SCHEMBL28410098 | 0.78 | MAPT (0.51) | MEN1KMT2AKDM4ESMN1; SMN2ATM | |
| SCHEMBL3490695 | 0.78 | CA2 (0.57) | SLC6A4 | |
| SCHEMBL2407621 | 0.78 | SMN1; SMN2 (0.46) | MEN1KMT2AKDM4ESMN1; SMN2ATM | |
| SCHEMBL10695731 | 0.77 | MMP12 (0.45) | HAO1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9577395 | 0.77 | F2 (0.57) | F2PLGPRSS1PRSS2C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| CN-100491361-C | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1761655-A | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-04-19 | — | — | CN | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1587800-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | Astellas Pharma Inc. (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004067521-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | HAO1 61/4885F2 2708/4885PLG 553/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | HAO1 1770/4885F2 2528/4885PLG 3811/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | HAO1 24/4885F2 3066/4885PLG 1216/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | HAO1 1770/4885F2 2528/4885PLG 3811/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | HAO1 121/4885F2 3602/4885PLG 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.